


Name	Ross Soo	
Country	Singapore	
Organization	National University Hospital	
Current Position	Senior Consultant	

Educational Background

M.B., B.S., Monash University, Australia.
Fellow of the Royal Australasian College of Physicians
Doctor of Philosophy, University Western Australia

Professional Experiences

1. Senior Consultant, Department of Haematology-Oncology, National University Hospital
2. Member of the Long-term International Fellowship (LIFe) Subcommittee of the Grant Selection Committee of the Conquer Cancer Foundation of ASCO, since 2018
3. Chair, National Healthcare Group Domain-Specific Review Board B
4. Deputy Editor, JTO Clinical and Research Reports, since 2021
5. Associate Editor, Lung Cancer, since 2017
6. Associate Editor, Therapeutic Advances Medical Oncology, since 2021
7. Member, Thoracic Scientific Committee, ETOP IBCSG Partners Foundation, 2021
8. Member, ESMO Clinical Practice Guidelines (Lung and Chest tumours) 2022-current
9. Member IASLC CME Committee 2021-current

Professional Organizations

1. Royal Australasian College of Physicians (RACP)
2. Singapore Society of Oncology (SSO)
3. American Society of Clinical Oncology (ASCO)
4. International Association for the Study of Lung Cancer (IASLC)
5. European Society for Medical Oncology (ESMO)
6. British Thoracic Oncology Group (BTOG)

Main Scientific Publications

1. A randomized phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. *Ann Oncol.* 2022 Feb;33(2):181-192
2. Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. *Nat Commun.* 2016 Jun 21;7:11702
3. Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBP α expression. *Sci Transl Med.* 2016 Aug 3;8(350):350ra104.
4. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. *Sci Transl Med.* 2013 Dec 18;5(216):216ra177
5. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. *Nat Med.* 2012 Mar 18;18(4):521-8
6. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. *Cell.* 2012 Jan 20;148(1-2):259-72.